Gliadel Wafer (carmustine in polifeprosan 20)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Carmustine, a nitrosourea-derivative alkylating agent, is an antineoplastic agent.

USES: This medication is an implant used to treat certain types of brain tumors (such as malignant glioma). The implant is a combination product (wafer) made of carmustine and polifeprosan 20. Carmustine belongs to a class of drugs known as alkylating agents.

It works by slowing or stopping the growth of cancer cells. Polifeprosan 20 helps control the release of carmustine in the brain.

Generic name: carmustine in polifeprosan 20
Pronunciation: (kar-MUS-teen/POL-ee-FEP-roe-san)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Gliadel Wafer

Intelligence content is not available yet.

Indications

The following indications are listed for Gliadel Wafer:

  • Glioblastoma Multiforme
  • Malignant Glioma

Also known as: Grade Iv Astrocytoma, Malignant Glial Tumor, Malignant Gliocytoma, Malignant Neurogliocytoma, Malignant Neuroglioma, Malignant Neurospongioma.

Dosing

No dosing information is available for this tab.

Drug interactions

Interactions of carmustine wafers with other drugs have not been formally studied. In clinical trials of patients undergoing surgery and intracranial implantation of carmustine wafers for recurrent malignant glioma, chemotherapy was withheld for at least 4 weeks (6 weeks for nitrosoureas) prior to and 2 weeks after surgery. The short-term or long-term toxicity of carmustine wafers used in conjunction with systemic chemotherapy has not been fully evaluated.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data